Maternal ancestry and hematological cancer risk: case-control study in an Argentinean population.
María Belén CerlianiAndrea Constanza MayordomoAnaclara Sanchez DovaJulieta Natalia SoarezJosefina Fuhr EtcheverryTamara Alejandra PiñeroAndrea Romina CajalFederico JaukHernán García-RivelloCarlos Alberto VaccaroSilvina Mariel RichardClaudio Marcelo BraviWalter Hernán PavicicPublished in: Personalized medicine (2021)
Aim: We investigated the role of maternal ancestry in neoplastic hematological malignancies (HMs) risk in a population from Central Argentina. Materials & methods: We analyzed 125 cases with HMs and 310 controls from a public hospital, and a set of 202 colorectal, breast, lung, and hematologic cancer patients from a private hospital. Results: A decreased risk for HMs was associated with the Native American haplogroup B2 (odds ratio = 0.49; 95% CI: 0.25-0.92; p = 0.02). The sub-Saharan African parahaplogroup L was associated with higher susceptibility for disease (odds ratio = 3.10; 95% CI: 1.04-9.31; p = 0.043). Although the mean ancestral proportions in the total studied population was as published (61.7% Native American, 34.6% European and 3.7% African), an unequal distribution was observed between hospitals. Conclusion: We confirmed the tri-hybrid nature of the Argentinean population, with proportions varying within the country. Our finding supports the notion that associated haplogroup is population and cancer specific.